logo

For the Inventor, By the Inventor

Derry, NH, United States of America

Mac Arthur Johnson, Jr

This inventor holds 12 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignees: Vertex Pharmaceuticals, Inc., Merck Patent Gmbh. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mac Arthur Johnson, Jr. Retrieved from https://idiyas.com/inventor/mac-arthur-johnson-jr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 

% Patents Active = 83.3

 

Average Co-Inventor Count = 22.5

ph-index = 2

Forward Citations = 14(Granted Patents)


Company Filing History:

goldMedal12 out of 1,167 
 
Vertex Pharmaceuticals, Inc.
 patents
silverMedal3 out of 3,022 
 
Merck Patent Gmbh
 patents
where one patent can have more than one assignee

Years Active: 2020-2026

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 12662471 - 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) (2026-06-23),
2. 12624028 - 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) (2026-05-12),
3. 12502376 - Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) (2025-12-23),
4. 12384790 - Pteridinone compounds and uses thereof (2025-08-12),
5. 12331057 - Modulators of alpha-1 antitrypsin (2025-06-17),
6. 12195453 - Antiproliferation compounds and uses thereof (2025-01-14),
7. 11884672 - Modulators of alpha-1 antitrypsin (2024-01-30),
8. 11623924 - Modulators of alpha-1 antitrypsin (2023-04-11),
9. 11572364 - Pteridinone compounds and uses thereof (2023-02-07),
10. 11440907 - Antiproliferation compounds and uses thereof (2022-09-13),
11. 11059826 - Pteridinone compounds and uses thereof (2021-07-13),
12. 10815225 - Antiproliferation compounds and uses thereof (2020-10-27),

Title: The Innovations of Mac Arthur Johnson, Jr.

Introduction

Mac Arthur Johnson, Jr., a prominent inventor based in Derry, NH, has made significant contributions to the field of pharmaceuticals. With a total of nine patents to his name, his work mainly focuses on developing novel compounds for treating serious medical conditions such as cancer and alpha-1 antitrypsin deficiency.

Latest Patents

Among his latest innovations is the patent for Pteridinone compounds and their uses. This invention presents compounds that are useful for treating cellular proliferative disorders, including cancer. Additionally, Johnson has developed modulators of alpha-1 antitrypsin, providing compounds that are beneficial for treating alpha-1 antitrypsin deficiency (AATD). These patents highlight his dedication to addressing critical health issues through innovative pharmaceutical solutions.

Career Highlights

Throughout his career, Mac Arthur Johnson, Jr. has worked with renowned companies such as Vertex Pharmaceuticals, Inc. and Merck Patent GmbH. His experience in these leading pharmaceutical organizations has helped him refine his skills in drug development and patent innovation.

Collaborations

Johnson has collaborated with notable coworkers like Michael John Boyd and Qing Tang. These partnerships have enabled him to combine expertise and foster a collaborative environment around complex pharmaceutical challenges.

Conclusion

Mac Arthur Johnson, Jr. exemplifies the spirit of innovation through his dedicated work in the pharmaceutical industry. His contributions have not only resulted in numerous patents but have also paved the way for advancements that can improve the quality of life for many individuals facing serious health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…